| Objective:1 To investigate the efficacy and safety of intravitreous injection ofconbercept for macular edema secondary to nonischemic retinal vein occlusion(RVO),during 6 months period.2 To investigate factors of the curative effec in patients with intravitreous injection of conbercept for macular edema secondary to non ischemic retinal vein occlusion.Methods:This prospective,controlled study examined patients presenting to th-e Second Hospital of Hebei Medical University with ME secondary to non ischemic RVO between February 2015 and August 2016.Patients' courses of disease are less than 12 months from the emergence of symptoms to treatment.After patients informed consent and make the choice,we injected Conbercept into their vitreous cavities.The three group wereinjected 1 times,then repeated injection according to the changes of visual acuity and OCT examination.The BCVA,OCT,Intraocular pressure changes and the times of injections were compared between the three groups before or after treatment.Analysis of Statistics:Using SPSS 21.0 statistical software,vision and CMT changes before and after treatment were compared by t test,and the changes between three groups were compared by ANOVA.It has significant statistically meaning if P<0.05.Result:A total of 37 patients with 37 eyes were included in the study.Among them,there are 18 female and 19 male;their ages are from 23 years old to 73 years old;their best vision is 0.2,the worst one is 1,andtheir average is 0.52 ±0.18.The least vesicle height of cystoid macular edema was 257?m,the largest one is 873?m,their average is(474.92 ±125.48)?m.According to gender,age,early vision,early height of cystoidmacular edema,divided into groups.1 The gender and curative effect: It does not have significant statistically meaning(P>0.05)2 The age and curative effect: It does not have significant statistically meaning(P>0.05)3 The initial BCVA and curative effect: There was close relationship between initial BCVA and curative effect,the difference was significant(P<0.05).4 The initial CMT and curative effect: There was close relationship between initial CMT and curative effect,the difference was significant(P<0.05).5.1 After treatment,the differences of BCVA in all groups were statistically significant(P1 <0.05,P2 <0.05,P3<0.05).5.2 There was significant difference(t2 =0.45,P2 >0.05)of the CMT decreasing between before and after the treatment in each group.5.3 Compared with before and after treatment in group mean differenceof 1month,3 months and 6 months,BCVA respectively 0.32 ± 0.12,0.32 ± 0.13 and 0.37 ± 0.11;0.38 ± 0.13,0.42 ± 0.17 and 0.44 ± 0.13;0.21 ± 0.16,0.20 ±0.12 and 0.22 ± 0.15.The difference among the three,the difference was statistically significant(F= 5.10,6.81,7.89;P<0.05).5.4 Compared with three groups before and treatment after 1 month,3months and 6 months,the average CMT difference respectively(249.86±141.57)?m,(248.14 ± 138.43)?m,(258.00 ± 139.91)?m,(294.64 ± 130.03)?m,(297.00 ± 136.50)?m,(300.18 ± 138.52)?m;(248.33 ± 83.85)?m,(255.75 ± 83.84)?m,(256.08 ± 84.16)?m,the differences among the three comparison were no statistically meter(F=0.537,0.539,0.466;P>0.05).5.5 The average number of injections administered in the early group was 2.29± 1.27,in the mid group was 2.55 ± 0.68 and in the late grou-p was 2.92 ±1.00.And the difference of three groups was no significant(P>0.05).5.6 IOP: No significant differences were observed from baseline IOP values in either group at any time point examined.Additionally,there wasno differencein IOP between the three groups at 1,3,6,9,or 12 months.Systemic adverse reactions,and persistent intraocular pressure elevation,complications were never found in the follow-up period.Conclusion:1 Intravitreous injection of conbercept is a safe and effective appro-ach for non ischemic retinal vein occlusion(RVO),which can significan-tly improve visual and reduce CMT.2 the duration of the course of disease,the level of BCVA and CMT with the first visit hospitalization are main factors affecting the trea-tment efficacy. |
PDF Full Text Request